Author Correction: Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.

Journal

Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015

Informations de publication

Date de publication:
05 2020
Historique:
pubmed: 16 4 2020
medline: 16 4 2020
entrez: 16 4 2020
Statut: ppublish

Résumé

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Identifiants

DOI: 10.1038/s41591-020-0864-x PMID: 32291416 PMC: PMC7819238
pubmed: 32291416
doi: 10.1038/s41591-020-0864-x
pii: 10.1038/s41591-020-0864-x
pmc: PMC7819238
mid: NIHMS1651002
doi:

Types de publication

Journal Article Published Erratum

Langues

eng

Sous-ensembles de citation

IM

Pagination

803

Subventions

Organisme : Intramural NIH HHS
ID : Z01 BC010984
Pays : United States

Commentaires et corrections

Type : ErratumFor

Auteurs

Jennifer N Brudno (JN)

Experimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.

Norris Lam (N)

Experimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.

Danielle Vanasse (D)

Experimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.

Yueh-Wei Shen (YW)

Kite Pharma, Santa Monica, CA, USA.

Jeremy J Rose (JJ)

Experimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.

John Rossi (J)

Kite Pharma, Santa Monica, CA, USA.

Allen Xue (A)

Kite Pharma, Santa Monica, CA, USA.

Adrian Bot (A)

Kite Pharma, Santa Monica, CA, USA.

Nathalie Scholler (N)

Kite Pharma, Santa Monica, CA, USA.
ORCID: 0000-0003-3743-7102

Lekha Mikkilineni (L)

Medical Oncology/Hematology Fellowship Program, NCI, Bethesda, MD, USA.

Mark Roschewski (M)

Lymphoid Malignancy Branch, Center for Cancer Research, NCI, NIH Bethesda, Bethesda, MD, USA.

Robert Dean (R)

Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA.

Raul Cachau (R)

Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
ORCID: 0000-0001-9260-2102

Philippe Youkharibache (P)

Cancer Data Science Lab, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Rashmika Patel (R)

Office of Regulatory Affairs, NCI, NIH, Bethesda, MD, USA.

Brenna Hansen (B)

Experimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.

David F Stroncek (DF)

Center for Cellular Engineering, Clinical Center, NIH, Bethesda, MD, USA.

Steven A Rosenberg (SA)

Surgery Branch, Center for Cancer Research, NCI, NIH Bethesda, Bethesda, MD, USA.

Ronald E Gress (RE)

Experimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.

James N Kochenderfer (JN)

Experimental Transplantation and Immunotherapy Branch, Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA. kochendj@mail.nih.gov.
ORCID: 0000-0002-4362-9875

Classifications MeSH